secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001193125-26-011104
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports $1.6B cash; KT-621 Phase 2b AD data by mid-2027, asthma data late-2027
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities of $1.6B as of Dec 31, 2025; runway into 2029.
- KT-621 Phase 2b BROADEN2 trial in AD enrolling, data expected by mid-2027; BREADTH Phase 2b asthma trial initiated, data late-2027.
- KT-579 Phase 1 healthy volunteer trial expected to start 1Q26 with data in 2H26; IRF5 degrader for lupus, RA.
- At least one new first-in-class oral immunology development candidate to advance towards IND in 2026.
- Partnered programs: KT-485/SAR447971 (IRAK4) with Sanofi Phase 1 expected in 2026; CDK2 program with Gilead ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/0001193125-26-011104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/d78447d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-011104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer